Basal sFAS/sFASL ratio and FAS polymorphisms, as a prognostic marker, in advanced colorectal carcinoma patients (ACRC), treated with oxaliplatin-based chemotherapy.

被引：0
|
作者：
Gascon, P
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：278S / 278S
页数：1
相关论文
共 50 条
  • [21] ERCC5 promoter polymorphisms at-763 and+25 predict the response to oxaliplatin-based chemotherapy in patients with advanced colorectal cancer
    Chen, Jianfang
    Xie, Fangwei
    Chen, Keli
    Wang, Dong
    Jiang, Heng
    Li, Jianjun
    Pan, Feng
    Chen, Shixu
    Zhang, Yanling
    Ruan, Zhihua
    Huang, Haihui
    Zou, Lan
    Liang, Houjie
    CANCER BIOLOGY & THERAPY, 2009, 8 (14) : 1424 - 1430
  • [22] Angiogenesis gene polymorphisms and clinical outcome of metastatic colorectal cancer treated with first-line bevacizumab and oxaliplatin-based chemotherapy
    Gerger, A.
    Zhang, W.
    Yang, D.
    Bohanes, P. O.
    Ning, Y.
    Winder, T.
    Labonte, M. J.
    Wilson, P. M.
    Benhaim, L.
    El-Khoueiry, R.
    Absenger, G.
    El-Khoueiry, A. B.
    Iqbal, S.
    Lenz, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [23] Tumor budding, an important prognostic factor in stage III colon cancer patients treated with oxaliplatin-based chemotherapy
    Basile, D.
    Broudin, C.
    Emile, J-F.
    Falcoz, A.
    Toullec, C.
    Bennouna, J.
    Louvet, C.
    Desrame, J.
    Fratte, S.
    Andre, T.
    Taieb, J.
    Svrcek, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S533 - S533
  • [24] DNA repair genes XPC, XPG polymorphisms: Relation to the risk of colorectal carcinoma and therapeutic outcome with oxaliplatin-based adjuvant chemotherapy
    Liu, Duo
    Wu, Hui-zhe
    Zhang, Yi-ning
    Kang, Hui
    Sun, Ming-jun
    Wang, En-hua
    Yang, Xiu-li
    Lian, Min-qiong
    Yu, Zhao-jin
    Zhao, Lin
    Olopade, Olufunmilayo I.
    Wei, Min-jie
    MOLECULAR CARCINOGENESIS, 2012, 51 : E83 - E93
  • [25] Hyaluronic Acid as a Marker of Hepatic Sinusoidal Obstruction Syndrome Secondary to Oxaliplatin-Based Chemotherapy in Patients with Colorectal Liver Metastases
    van den Broek, Maartje A. J.
    Vreuls, Celien P. H.
    Winstanley, Ali
    Jansen, Rob L. H.
    van Bijnen, Annemarie A.
    Dello, Simon A. W. G.
    Bemelmans, Marc H.
    Dejong, Cornelis H. C.
    Driessen, Ann
    Damink, Steven W. M. Olde
    ANNALS OF SURGICAL ONCOLOGY, 2013, 20 (05) : 1462 - 1469
  • [26] Hyaluronic Acid as a Marker of Hepatic Sinusoidal Obstruction Syndrome Secondary to Oxaliplatin-Based Chemotherapy in Patients with Colorectal Liver Metastases
    Maartje A. J. van den Broek
    Celien P. H. Vreuls
    Ali Winstanley
    Rob L. H. Jansen
    Annemarie A. van Bijnen
    Simon A. W. G. Dello
    Marc H. Bemelmans
    Cornelis H. C. Dejong
    Ann Driessen
    Steven W. M. Olde Damink
    Annals of Surgical Oncology, 2013, 20 : 1462 - 1469
  • [27] Handy prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer
    Chibaudel, B.
    Tournigand, C.
    Bonnetain, F.
    Andre, T.
    Lledo, G.
    Maindrault-Goebel, F.
    Larsen, A. K.
    Louvet, C.
    de Gramont, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [28] Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy.: A report of the AIO Colorectal Study Group
    Mueller, C. I.
    Schulmann, K.
    Reinacher-Schick, A.
    Andre, N.
    Arnold, D.
    Tannapfel, A.
    Arkenau, H.
    Hahn, S. A.
    Schmoll, S. H. -J.
    Porschen, R.
    Schmiegel, W.
    Graeven, U.
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2008, 23 (11) : 1033 - 1039
  • [29] Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group
    C. I. Müller
    K. Schulmann
    A. Reinacher-Schick
    N. Andre
    D. Arnold
    A. Tannapfel
    H. Arkenau
    S. A. Hahn
    S. H.-J. Schmoll
    R. Porschen
    W. Schmiegel
    U. Graeven
    International Journal of Colorectal Disease, 2008, 23 : 1033 - 1039
  • [30] Predictive role of a pharmacogenetic profiling in patients with advanced colorectal cancer (ACRC) treated with first-line, 5-fluorouracil/oxaliplatin chemotherapy
    Graziano, F.
    Ruzzo, A. M.
    Loupakis, F.
    Canestrari, E.
    Santini, D.
    Catalano, V
    Ficarelli, R.
    Mari, D.
    Bisonni, R.
    Masi, G.
    Schiavon, G.
    Safina, V
    Maltese, P.
    Pizzagalli, F.
    Giordani, P.
    Lippe, P.
    Alessandroni, P.
    Giustini, L.
    Falcone, A.
    Tonini, G.
    Silva, R. R.
    Mattioli, R.
    Menichetti, E. T.
    Testa, E.
    Lai, V
    Magnani, M.
    ANNALS OF ONCOLOGY, 2006, 17 : XI42 - XI43
12345